

Alina Malyutina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1542852/publications.pdf>

Version: 2024-02-01

9
papers

646
citations

1306789

7
h-index

1473754

9
g-index

14
all docs

14
docs citations

14
times ranked

948
citing authors

#	ARTICLE	IF	CITATIONS
1	SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets. <i>Genomics, Proteomics and Bioinformatics</i> , 2022, 20, 587-596.	3.0	159
2	DrugComb: an integrative cancer drug combination data portal. <i>Nucleic Acids Research</i> , 2019, 47, W43-W51.	6.5	153
3	DEqMS: A Method for Accurate Variance Estimation in Differential Protein Expression Analysis. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 1047-1057.	2.5	127
4	Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. <i>PLoS Computational Biology</i> , 2019, 15, e1006752.	1.5	106
5	Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles. <i>Database: the Journal of Biological Databases and Curation</i> , 2018, 2018, 1-13.	1.4	36
6	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. <i>Haematologica</i> , 2020, 105, 1527-1538.	1.7	19
7	Combined gene essentiality scoring improves the prediction of cancer dependency maps. <i>EBioMedicine</i> , 2019, 50, 67-80.	2.7	18
8	Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 4125-4139.	2.5	6
9	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. <i>Blood</i> , 2018, 132, 264-264.	0.6	5